Market Overview:
The global selective agonists market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of cardiovascular diseases and other chronic diseases, rising geriatric population, and technological advancements in the field of selective agonists. The global selective agonists market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into α1 selective agonists, α2 selective agonists, β1 selectives Agonistesβ2 Selective Agonistes), and others (γ-aminobutyric acid [GABA] receptor modulators). On the basis of application,the market is segmented into paroxysmal supraventricular tachycardia (PSVT), eye drops,, anaphylaxis,, cardiac arrest,, chronic heart failure (CHF), myocardial infarction (MI), postoperative hypotension)and others(gastrointestinal disorders,. By region,. North America accounted for largest share in 2017 due to well-developed healthcare infrastructure and high adoption rateof novel technologies.
Product Definition:
A selective agonist is a type of drug that binds to and activates only a specific receptor type, while leaving other receptor types unaffected. This selectivity may be due to the chemical structure of the drug, or to the location of the receptors within the body. Selective agonists are important because they can be used to selectively activate certain physiological processes without affecting others.
α1 Selective Agonists:
α1 selective agonists are protein-based drugs that bind to the cannabinoid receptor and act as a full agonist. They have higher affinity for CB1 than CB2 receptors. The drug class includes buspirone, (5-HT 1A partial agonist) RSHA, and AMPA receptor antagonist.
α2 Selective Agonists:
α2 selective agonists are a type of drug that binds to the α2 subunit of voltage-gated ion channels and triggers an action potential in presynaptic terminals. Agonists that bind directly to the extracellular domain of the receptor are referred to as full length; whereas, those that bind only intracellularly or transcellularly are termed as partial agonists.
Application Insights:
Paroxysmal supraventricular tachycardia (PSVT) was the most prominent application segment in the global selective agonists market in 2017. The growing prevalence of PSVT is one of the major factors driving this segment. According to a study published by NCBI, around 1% to 2% of all patients suffering from atrial fibrillation develop paroxysmal supraventricular tachycardia (PSVT). Moreover, according to another study conducted by WHO, around 500 thousand people suffer from PSVT globally and it is expected that over 1 million individuals will be affected by 2030. This factor can be attributed towards high demand for Selective Agonist Drugs (SADs) for treatment of paroxysmal SVT as they have fewer side effects as compared to other drugs used for treating arrhythmia such as anticoagulants and cardiac glycosides.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high R&D investment by them and their efforts to commercialize products at a relatively faster pace.
Asia Pacific is expected to grow at a lucrative rate over the forecast period owing to increasing healthcare expenditure and awareness about these drugs among physicians and patients. Moreover, rising number of approvals for new molecules in this region is anticipated to fuel growth during the forecast period.
Growth Factors:
- Increasing demand for selective agonists in the treatment of various diseases such as cancer, obesity, and diabetes.
- Rising prevalence of target diseases that can be treated with selective agonists.
- Growing research and development activities for the discovery of novel selective agonists molecules.
- Technological advancements in the field of drug discovery that are aiding the development of better selective agonist molecules.
Scope Of The Report
Report Attributes
Report Details
Report Title
Selective Agonists Market Research Report
By Type
α1 Selective Agonists, α2 Selective Agonists, β1 Selective Agonists, β2 Selective Agonists
By Application
Paroxysmal Supraventricular Tachycardia, Eye Drops, Anaphylaxis, Cardiac Arrest, Anaphylaxis, Cardiac Arrest, Chronic Heart Failure, Myocardial Infarction, Postoperative Hypotension
By Companies
Merck, Bausch Health Companies, Pfizer, Sterling Winthrop, Sanofi, Paragon BioTeck, West-Ward Pharmaceuticals , Biosyent Pharma , Novartis, Omega Laboratories, Medical Purchasing Solutions, Avadel Legacy Pharmaceuticals, Amneal Biosciences, Cipla USA, Par Pharmaceutical, Glaxosmithkline, Teva, Bayer, Impax Generics, Mylan Pharmaceuticals, Physicians Total Care, Cadila Pharnmaceuticals, Alembic Pharmaceuticals, Allergan, Mylan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
207
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Selective Agonists Market Report Segments:
The global Selective Agonists market is segmented on the basis of:
Types
α1 Selective Agonists, α2 Selective Agonists, β1 Selective Agonists, β2 Selective Agonists
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Paroxysmal Supraventricular Tachycardia, Eye Drops, Anaphylaxis, Cardiac Arrest, Anaphylaxis, Cardiac Arrest, Chronic Heart Failure, Myocardial Infarction, Postoperative Hypotension
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Bausch Health Companies
- Pfizer
- Sterling Winthrop
- Sanofi
- Paragon BioTeck
- West-Ward Pharmaceuticals
- Biosyent Pharma
- Novartis
- Omega Laboratories
- Medical Purchasing Solutions
- Avadel Legacy Pharmaceuticals
- Amneal Biosciences
- Cipla USA
- Par Pharmaceutical
- Glaxosmithkline
- Teva
- Bayer
- Impax Generics
- Mylan Pharmaceuticals
- Physicians Total Care
- Cadila Pharnmaceuticals
- Alembic Pharmaceuticals
- Allergan
- Mylan
Highlights of The Selective Agonists Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- α1 Selective Agonists
- α2 Selective Agonists
- β1 Selective Agonists
- β2 Selective Agonists
- By Application:
- Paroxysmal Supraventricular Tachycardia
- Eye Drops
- Anaphylaxis
- Cardiac Arrest
- Anaphylaxis
- Cardiac Arrest
- Chronic Heart Failure
- Myocardial Infarction
- Postoperative Hypotension
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Selective Agonists Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Selective agonists are drugs that selectively activate a certain type of receptor in the body. This can help to improve or treat symptoms associated with that receptor, such as pain, inflammation, and anxiety.
Some of the major players in the selective agonists market are Merck, Bausch Health Companies, Pfizer, Sterling Winthrop, Sanofi, Paragon BioTeck, West-Ward Pharmaceuticals , Biosyent Pharma , Novartis, Omega Laboratories, Medical Purchasing Solutions, Avadel Legacy Pharmaceuticals, Amneal Biosciences, Cipla USA, Par Pharmaceutical, Glaxosmithkline, Teva, Bayer, Impax Generics, Mylan Pharmaceuticals, Physicians Total Care, Cadila Pharnmaceuticals, Alembic Pharmaceuticals, Allergan, Mylan.
The selective agonists market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Selective Agonists Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Selective Agonists Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Selective Agonists Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Selective Agonists Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Selective Agonists Market Size & Forecast, 2018-2028
4.5.1 Selective Agonists Market Size and Y-o-Y Growth
4.5.2 Selective Agonists Market Absolute $ Opportunity
Chapter 5 Global Selective Agonists Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Selective Agonists Market Size Forecast by Type
5.2.1 α1 Selective Agonists
5.2.2 α2 Selective Agonists
5.2.3 β1 Selective Agonists
5.2.4 β2 Selective Agonists
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Selective Agonists Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Selective Agonists Market Size Forecast by Applications
6.2.1 Paroxysmal Supraventricular Tachycardia
6.2.2 Eye Drops
6.2.3 Anaphylaxis
6.2.4 Cardiac Arrest
6.2.5 Anaphylaxis
6.2.6 Cardiac Arrest
6.2.7 Chronic Heart Failure
6.2.8 Myocardial Infarction
6.2.9 Postoperative Hypotension
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Selective Agonists Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Selective Agonists Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Selective Agonists Analysis and Forecast
9.1 Introduction
9.2 North America Selective Agonists Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Selective Agonists Market Size Forecast by Type
9.6.1 α1 Selective Agonists
9.6.2 α2 Selective Agonists
9.6.3 β1 Selective Agonists
9.6.4 β2 Selective Agonists
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Selective Agonists Market Size Forecast by Applications
9.10.1 Paroxysmal Supraventricular Tachycardia
9.10.2 Eye Drops
9.10.3 Anaphylaxis
9.10.4 Cardiac Arrest
9.10.5 Anaphylaxis
9.10.6 Cardiac Arrest
9.10.7 Chronic Heart Failure
9.10.8 Myocardial Infarction
9.10.9 Postoperative Hypotension
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Selective Agonists Analysis and Forecast
10.1 Introduction
10.2 Europe Selective Agonists Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Selective Agonists Market Size Forecast by Type
10.6.1 α1 Selective Agonists
10.6.2 α2 Selective Agonists
10.6.3 β1 Selective Agonists
10.6.4 β2 Selective Agonists
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Selective Agonists Market Size Forecast by Applications
10.10.1 Paroxysmal Supraventricular Tachycardia
10.10.2 Eye Drops
10.10.3 Anaphylaxis
10.10.4 Cardiac Arrest
10.10.5 Anaphylaxis
10.10.6 Cardiac Arrest
10.10.7 Chronic Heart Failure
10.10.8 Myocardial Infarction
10.10.9 Postoperative Hypotension
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Selective Agonists Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Selective Agonists Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Selective Agonists Market Size Forecast by Type
11.6.1 α1 Selective Agonists
11.6.2 α2 Selective Agonists
11.6.3 β1 Selective Agonists
11.6.4 β2 Selective Agonists
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Selective Agonists Market Size Forecast by Applications
11.10.1 Paroxysmal Supraventricular Tachycardia
11.10.2 Eye Drops
11.10.3 Anaphylaxis
11.10.4 Cardiac Arrest
11.10.5 Anaphylaxis
11.10.6 Cardiac Arrest
11.10.7 Chronic Heart Failure
11.10.8 Myocardial Infarction
11.10.9 Postoperative Hypotension
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Selective Agonists Analysis and Forecast
12.1 Introduction
12.2 Latin America Selective Agonists Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Selective Agonists Market Size Forecast by Type
12.6.1 α1 Selective Agonists
12.6.2 α2 Selective Agonists
12.6.3 β1 Selective Agonists
12.6.4 β2 Selective Agonists
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Selective Agonists Market Size Forecast by Applications
12.10.1 Paroxysmal Supraventricular Tachycardia
12.10.2 Eye Drops
12.10.3 Anaphylaxis
12.10.4 Cardiac Arrest
12.10.5 Anaphylaxis
12.10.6 Cardiac Arrest
12.10.7 Chronic Heart Failure
12.10.8 Myocardial Infarction
12.10.9 Postoperative Hypotension
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Selective Agonists Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Selective Agonists Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Selective Agonists Market Size Forecast by Type
13.6.1 α1 Selective Agonists
13.6.2 α2 Selective Agonists
13.6.3 β1 Selective Agonists
13.6.4 β2 Selective Agonists
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Selective Agonists Market Size Forecast by Applications
13.10.1 Paroxysmal Supraventricular Tachycardia
13.10.2 Eye Drops
13.10.3 Anaphylaxis
13.10.4 Cardiac Arrest
13.10.5 Anaphylaxis
13.10.6 Cardiac Arrest
13.10.7 Chronic Heart Failure
13.10.8 Myocardial Infarction
13.10.9 Postoperative Hypotension
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Selective Agonists Market: Competitive Dashboard
14.2 Global Selective Agonists Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 Bausch Health Companies
14.3.3 Pfizer
14.3.4 Sterling Winthrop
14.3.5 Sanofi
14.3.6 Paragon BioTeck
14.3.7 West-Ward Pharmaceuticals
14.3.8 Biosyent Pharma
14.3.9 Novartis
14.3.10 Omega Laboratories
14.3.11 Medical Purchasing Solutions
14.3.12 Avadel Legacy Pharmaceuticals
14.3.13 Amneal Biosciences
14.3.14 Cipla USA
14.3.15 Par Pharmaceutical
14.3.16 Glaxosmithkline
14.3.17 Teva
14.3.18 Bayer
14.3.19 Impax Generics
14.3.20 Mylan Pharmaceuticals
14.3.21 Physicians Total Care
14.3.22 Cadila Pharnmaceuticals
14.3.23 Alembic Pharmaceuticals
14.3.24 Allergan
14.3.25 Mylan
